Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120M
-
Number of holders
-
232
-
Total 13F shares, excl. options
-
126M
-
Shares change
-
-1.29M
-
Total reported value, excl. options
-
$2.37B
-
Value change
-
-$12.8M
-
Put/Call ratio
-
0.33
-
Number of buys
-
114
-
Number of sells
-
-104
-
Price
-
$18.85
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q3 2025
264 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock as of Q3 2025.
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) has 232 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 126M shares
.
Largest 10 shareholders include JENNISON ASSOCIATES LLC (12.3M shares), Rubric Capital Management LP (10.7M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (10.5M shares), Frazier Life Sciences Management, L.P. (9.87M shares), BlackRock, Inc. (8.57M shares), VANGUARD GROUP INC (7.15M shares), Polar Capital Holdings Plc (5.3M shares), STATE STREET CORP (4.64M shares), GILDER GAGNON HOWE & CO LLC (4.43M shares), and MORGAN STANLEY (4.28M shares).
This table shows the top 232 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.